Life Sciences

Pfizer to settle Bextra, Celebrex claims for $894M

Pharma Compliance Alert, October 22, 2008

Pfizer has agreed in principle to pay $894 million to settle all lawsuits related to its non-steroidal anti-inflammatory drugs Bextra and Celebrex, according to a company release.

Post a Comment





Please enter your comment below:


Please enter the text below:

    Healthcare Life Safety Compliance
  • Healthcare Life Safety Compliance

    Created exclusively for healthcare facility managers, plant operations professionals, and directors of engineering, this...

  • ePharm5 InDepth

    EPharm5 e-mail newsletter delivers the top 5 developments in pharma business innovation, with original research, interviews...

  • Medical Environment Update

    A subscription to Medical Environment Update pays for itself by saving you time sorting through complex regulations and...

  • Bloodborne Pathogens Training Video

    Meets OSHA requirements for training employees on the bloodborne pathogens standard!

  • Healthcare Marketing Advisor

    Healthcare Marketing Advisor provides concise, time-saving strategies for branding, promoting, and advertising your...

Most Popular